Although peritoneal dialysis (PD) is a widely accepted form of renal replacement therapy, concerns remain regarding the bioincompatible nature of standard PD fluid (PDF). Short-term studies of new biocompatible PDFs low in glucose degradation products (GDPs) reveal divergent results with respect to peritoneal integrity.
Methods
We studied 125 patients on maintenance PD who were assigned, by simple randomization, to receive either conventional or low-GDP PDF at PD initiation. Parameters of dialysis adequacy and peritoneal transport of small solutes were determined at initiation and after a period of maintenance PD at the time when serum and overnight effluent dialysate were simultaneously collected and assayed for various cytokines, chemokines, adipokines, and cardiac biomarkers. All patients were further followed prospectively for an average of 15 months from the day of serum and effluent collection to determine patient survival and cardiovascular events.
Results
Patients treated with conventional or low-GDP PDF were matched for sex, age, duration of dialysis, dialysis adequacy, and incidence of cardiovascular disease or diabetes. After an average of 2.3 years of PD treatment, the weekly total and peritoneal creatinine clearance, and the total and peritoneal Kt/V were comparable in the groups. However, urine output was higher in patients using low-GDP PDF despite there having been no difference between the groups at PD initiation. Patients using low-GDP PDF also experienced a slower rate of decline of residual glomerular filtration and urine output than did patients on conventional PDF. Compared with serum concentrations, effluent concentrations of tumor necrosis factor α, hepatocyte growth factor, macrophage migration inhibitory factor, interleukins 8 and 6, C-reactive protein, and leptin were found to be higher in both groups of patients after long-term PD, suggesting that the peritoneal cavity was the major source of those mediators. Compared with patients on low-GDP PDF, patients on conventional fluid showed elevated leptin and reduced adiponectin levels in serum and effluent. The effluent concentration of interleukin 8 was significantly lower in patients using low-GDP PDF. The survival rate and incidence of cardiovascular complications did not differ between these groups after maintenance PD for an average of 3.6 years.
Conclusions
It appears that low-GDP PDF results in an improvement of local peritoneal homeostasis through a reduction of chronic inflammatory status in the peritoneum.
BrownleeM., CeramiA., VlassaraH.Advanced glycation end products in tissue and the biochemical basis of diabetic complications.N Engl J Med1988; 318: 1315–21.
2.
NakamuraS., TachikawaT., TobitaK., MiyazakiS., SakaiS., MoritaT.Role of advanced glycation end products and growth factors in peritoneal dysfunction in CAPD patients.Am J Kidney Dis2003; 41(Suppl 1): S61–7.
3.
ChaudharyK., KhannaR.Biocompatible peritoneal dialysis solutions: do we have one?Clin J Am Soc Nephrol2010; 5: 723–32.
4.
LeeH.Y., ChoiH.Y., ParkH.C., SeoB.J., DoJ.Y., YunS.R.Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome.Nephrol Dial Transplant2006; 21: 2893–9.
5.
LeeH.Y., ParkH.C., SeoB.J., DoJ.Y., YunS.R., SongH.Y.Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance).Perit Dial Int2005; 25: 48–55.
6.
RippeB., SimonsenO., HeimbürgerO., ChristenssonA., HaraldssonB., StelinG.Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.Kidney Int2001; 59: 348–57.
7.
WilliamsJ.D., TopleyN., CraigK.J., MackenzieR.K., PischetsriederM., LageC.The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane.Kidney Int2004; 66: 408–18.
8.
SzetoC.C., ChowK.M., LamC.W., LeungC.B., KwanB.C., ChungK.Y.Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products—a 1-year randomized control trial.Nephrol Dial Transplant2007; 22: 552–9.
9.
DoJ.Y., KimY.L., ParkJ.W., ChangK.A., LeeS.H., RyuD.H.The association between the vascular endothelial growth factor–to–cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis.Perit Dial Int2008; 28(Suppl 3): S101–6.
10.
KimS., OhJ., KimS., ChungW., AhnC., KimS.G.Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study.Nephrol Dial Transplant2009; 24: 2899–908.
11.
LaiK.N., LoW.K.Optimal peritoneal dialysis for patients from Hong Kong.Perit Dial Int1999; 19(Suppl 3): S26–31.
12.
van OldenR.W., KredietR.T., StruijkD.G., AriszL.Measurement of residual renal function in patients treated with continuous ambulatory peritoneal dialysis.J Am Soc Nephrol1996; 7: 745–50.
13.
NolphK.D., MooreH.L., TwardowskiZ.J., KhannaR., ProwantB., MeyerM.Cross-sectional assessment of weekly urea and creatinine clearances in patients on continuous ambulatory peritoneal dialysis.ASAIO J1992; 38: M139–42.
14.
ZemelD., ImholzA.L., de WaartD.R., DinklaC., StruijkD.G., KredietR.T.Appearance of tumor necrosis factor-alpha and soluble TNF-receptors I and II in peritoneal effluent of CAPD.Kidney Int1994; 46: 1422–30.
15.
JörresA.Glucose degradation products in peritoneal dialysis: from bench to bedside.Kidney Blood Press Res2003; 26: 113–17.
16.
HondaK., NittaK., HoritaS., YumuraW., NiheiH., NagaiR.Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration.Nephrol Dial Transplant1999; 14: 1541–9.
17.
LaiK.N., LeungJ.C., ChanL.Y., LiF.F., TangS.C., LamM.F.Differential expression of receptors for advanced glycation end-products in peritoneal mesothelial cells exposed to glucose degradation products.Clin Exp Immunol2004; 138: 466–75.
18.
LeungJ.C., ChanL.Y., LiF.F., TangS.C., ChanK.W., ChanT.M.Glucose degradation products downregulate ZO-1 expression in human peritoneal mesothelial cells: the role of VEGF.Nephrol Dial Transplant2005; 20: 1336–49.
19.
OhE.J., RyuH.M., ChoiS.Y., YookJ.M., KimC.D., ParkS.H.Impact of low glucose degradation product bicarbonate/ lactate–buffered dialysis solution on the epithelial– mesenchymal transition of peritoneum.Am J Nephrol2010; 31: 58–67.
20.
ChertowG.M., LevinN.W., BeckG.J., DepnerT.A., EggersP.W., GassmanJ.J.on behalf of the FHN Trial Group. In-center hemodialysis six times per week versus three times per week.N Engl J Med2010; 363: 2287–300. [Erratum in: N Engl J Med 2011; 364: 93]
21.
FusshöllerA., PlailM., GrabenseeB., PlumJ.Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study.Nephrol Dial Transplant2004; 19: 2101–6.
22.
ChoiH.Y., KimD.K., LeeT.H., MoonS.J., HanS.H., LeeJ.E.The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial.Perit Dial Int2008; 28: 174–82.
23.
WeissL., StegmayrB., MalmstenG., TejdeM., HadimeriH., SiegertC.E.Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution.Perit Dial Int2009; 29: 647–55.
24.
FangW., MullanR., ShahH., MujaisS., BargmanJ.M., OreopoulosD.G.Comparison between bicarbonate/lactate and standard lactate dialysis solution in peritoneal transport and ultrafiltration: a prospective, crossover single-dwell study.Perit Dial Int2008; 28: 35–43.
25.
FanS.L., PileT., PunzalanS., RafteryM.J., YaqoobM.M.Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function.Kidney Int2008; 73: 200–6.
26.
PajekJ., KvederR., BrenA., GucekA., BucarM., SkoberneA.Short-term effects of bicarbonate/lactate–buffered and conventional lactate-buffered dialysis solutions on peritoneal ultrafiltration: a comparative crossover study.Nephrol Dial Transplant2009; 24: 1617–25.
27.
Haag-WeberM., KrämerR., HaakeR., IslamM.S., PrischlF., HaugU.Low-GDP fluid (Gambrosol Trio) attenuates decline of residual renal function in PD patients: a prospective randomized study.Nephrol Dial Transplant2010; 25: 2288–96.
28.
MartikainenT.A., TeppoA.M., Grönhagen-RiskaC., EkstrandA.V.Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane?Perit Dial Int2005; 25: 453–60.
29.
PajekJ., KvederR., BrenA., GucekA., IhanA., OsredkarJ.Short-term effects of a new bicarbonate/lactate–buffered and conventional peritoneal dialysis fluid on peritoneal and systemic inflammation in CAPD patients: a randomized controlled study.Perit Dial Int2008; 28: 44–52.
LeungJ.C., ChanL.Y., TamK.Y., TangS.C., LamM.F., ChengA.S.Regulation of CCN2/CTGF and related cytokines in cultured peritoneal cells under conditions simulating peritoneal dialysis.Nephrol Dial Transplant2009; 24: 458–69.
32.
YuM.A., ShinK.S., KimJ.H., KimY.I., ChungS.S., ParkS.H.HGF and BMP-7 ameliorate high glucose-induced epithelial-to-mesenchymal transition of peritoneal mesothelium.J Am Soc Nephrol2009; 20: 567–81.
33.
IkedaY., MurakamiA., FujimuraY., TachibanaH., YamadaK., MasudaD.Aggregated ursolic acid, a natural triterpenoid, induces IL-1beta release from murine peritoneal macrophages: role of CD36.J Immunol2007; 178: 4854–64.
34.
LeungJ.C., ChanL.Y., TangS.C., ChuK.M., LaiK.N.Leptin induces TGF-beta synthesis through functional leptin receptor expressed by human peritoneal mesothelial cell.Kidney Int2006; 69: 2078–86.
35.
WitowskiJ., TayamaH., KsiazekK., Wanic-KossowskaM., BenderT.O., JörresA.Human peritoneal fibroblasts are a potent source of neutrophil-targeting cytokines: a key role of IL-1beta stimulation.Lab Invest2009; 89: 414–24.
36.
TetaD., MaillardM., TedjaniA., Passlick-DeetjenJ., BurnierM.The effect of pH-neutral peritoneal dialysis fluids on adipokine secretion from cultured adipocytes.Nephrol Dial Transplant2007; 22: 862–9.
37.
AxelssonJ., Rashid QureshiA., SulimanM.E., HondaH., Pecoits-FilhoR., HeimbürgerO.Truncal fat mass as a contributor to inflammation in end-stage renal disease.Am J Clin Nutr2004; 80: 1222–9.
38.
XuL., JiangC.Q., LamT.H., LinJ.M., YueX.J., ChengK.K.The metabolic syndrome is associated with subclinical atherosclerosis independent of insulin resistance: the Guangzhou Biobank Cohort Study-CVD.Clin Endocrinol (Oxf)2010; 73: 181–8.
39.
TetaD., MaillardM., HalabiG., BurnierM.The leptin/ adiponectin ratio: potential implications for peritoneal dialysis.Kidney Int Suppl2008; (108): S112–18.
40.
LaiK.N., LeungJ.C.Inflammation in peritoneal dialysis.Nephron Clin Pract2010; 116: c11–18.
41.
HanS.H., ChoiH.Y., KimD.K., MoonS.J., LeeJ.E., YooT.H.Elevated cardiac troponin T predicts cardiovascular events in asymptomatic continuous ambulatory peritoneal dialysis patients without a history of cardiovascular disease.Am J Nephrol2009; 29: 129–35.
42.
PaniaguaR., AmatoD., MujaisS., VoneshE., RamosA., Correa-RotterR.Predictive value of brain natriuretic peptides in patients on peritoneal dialysis: results from the ADEMEX trial.Clin J Am Soc Nephrol2008; 3: 407–15.
43.
LamM.F., TangC., WongA.K., TongK.L., YuA.W., LiC.S.ASPD: a prospective study of adequacy in Asian patients on long term, small volume, continuous ambulatory peritoneal dialysis.Perit Dial Int2006; 26: 466–74.
44.
NicholsJ., GoingS., LoftinM., StewartD., NowickiE., PickrelJ.Comparison of two bioelectrical impedance analysis instruments for determining body composition in adolescent girls.Int J Body Compos Res2006; 4: 153–60.
45.
WoodrowG.Body composition analysis techniques in adult and pediatric patients: how reliable are they? how useful are they clinically?Perit Dial Int2007; 27(Suppl 2): S245–9.
